James J. Egan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
James J. Egan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Nizar Yonan
2 shared publicationsShe S. Lok
North West Lung Centre, Wythenshawe Hospital, Manchester, United Kingdom
2 shared publicationsAbdul K. Deiraniya
North West Lung Centre and Department of Cardiothoracic Surgery, Wythenshawe Hospital, and Public Health Laboratory, Withington Hospital, Manchester, England
1 shared publicationAndrew Fox
North West Lung Centre and Department of Cardiothoracic Surgery, Wythenshawe Hospital, and Public Health Laboratory, Withington Hospital, Manchester, England
1 shared publicationAndrew J. Turner
North West Lung Centre and Department of Cardiothoracic Surgery, Wythenshawe Hospital, and Public Health Laboratory, Withington Hospital, Manchester, England
1 shared publication- Ashley Woodcock
University of Manchester, Manchester, UK
1 shared publication
Latest Publications
- 1 November 1998
- Vol. 17 (11) , 1039-44
Pharmacologic therapy of idiopathic pulmonary fibrosis.
- 15 March 1998
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (5) , 747-752
PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE
Background. Rapid quantifiable diagnostic techniques for the diagnosis of cytomegalovirus (CMV) infection may predict patients at risk of CMV pneumonitis and allow preemptive antiviral treatment. Methods. Using CMV antigenemia as a prospective surveillance technique for CMV infection, we compared the outcome of preemptive treatment (PT) with ganciclovir, 10 mg/kg/day for 21 days directed by “high levels” of CMV antigenemia (PT group, n=19), with the outcome in a group of historical controls (n=18) treated with ganciclovir when CMV illness occurred. Greater than 50 antigen-positive cells per 2×105 polymorphonuclear leukocytes was considered to be high-level antigenemia. Results. Nine of the 18 controls developed high-level CMV antigenemia at a median of 33 days (range: 13-65 days) and 5 of the 9 developed CMV disease. Ten of the 19 PT group had high levels of CMV antigenemia detected at a median of 47 days (range: 20-63 days) and were given ganciclovir; none developed CMV disease. There was a significantly lower incidence of CMV disease in the PT group in comparison to controls (0 of 19 vs. 5 of 18:P=0.019). Conclusion. We have reduced the incidence of CMV disease using preemptive treatment, and because of a 100% negative predictive value, we omitted unnecessary antiviral prophylaxis for many at-risk patients.
- 15 March 1998
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (5) , 747-752
PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE
Background. Rapid quantifiable diagnostic techniques for the diagnosis of cytomegalovirus (CMV) infection may predict patients at risk of CMV pneumonitis and allow preemptive antiviral treatment. Methods. Using CMV antigenemia as a prospective surveillance technique for CMV infection, we compared the outcome of preemptive treatment (PT) with ganciclovir, 10 mg/kg/day for 21 days directed by “high levels” of CMV antigenemia (PT group, n=19), with the outcome in a group of historical controls (n=18) treated with ganciclovir when CMV illness occurred. Greater than 50 antigen-positive cells per 2×105 polymorphonuclear leukocytes was considered to be high-level antigenemia. Results. Nine of the 18 controls developed high-level CMV antigenemia at a median of 33 days (range: 13-65 days) and 5 of the 9 developed CMV disease. Ten of the 19 PT group had high levels of CMV antigenemia detected at a median of 47 days (range: 20-63 days) and were given ganciclovir; none developed CMV disease. There was a significantly lower incidence of CMV disease in the PT group in comparison to controls (0 of 19 vs. 5 of 18:P=0.019). Conclusion. We have reduced the incidence of CMV disease using preemptive treatment, and because of a 100% negative predictive value, we omitted unnecessary antiviral prophylaxis for many at-risk patients.